Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL ITTMANN and DOV KADMON.
Connection Strength
0.367
-
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
Score: 0.100
-
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
Score: 0.082
-
Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
Score: 0.038
-
Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
Score: 0.029
-
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242.
Score: 0.028
-
Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
Score: 0.024
-
Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
Score: 0.021
-
CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83.
Score: 0.017
-
The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
Score: 0.016
-
The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
Score: 0.013